Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High After Better-Than-Expected Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) reached a new 52-week high during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $38.75 and last traded at $38.6030, with a volume of 220537 shares. The stock had previously closed at $31.99.

The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Analysts Set New Price Targets

Several equities analysts have weighed in on ORKA shares. Wedbush reaffirmed an “outperform” rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Friday. UBS Group started coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective for the company. Stifel Nicolaus raised their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the sale, the insider owned 34,018 shares in the company, valued at $1,101,162.66. The trade was a 17.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 21,000 shares of company stock worth $663,530 over the last three months. Company insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently made changes to their positions in ORKA. Fairmount Funds Management LLC boosted its stake in Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after buying an additional 333,340 shares during the last quarter. Viking Global Investors LP bought a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $51,280,000. Deep Track Capital LP increased its stake in Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after acquiring an additional 676,865 shares in the last quarter. Finally, RTW Investments LP raised its holdings in shares of Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after acquiring an additional 112,499 shares in the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Trading Up 25.0%

The business has a 50-day moving average price of $32.92 and a 200 day moving average price of $27.50. The stock has a market capitalization of $1.94 billion, a P/E ratio of -21.51 and a beta of -0.38.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.